Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients

Breast Cancer Research and Treatment

Volumn 43, Issue 2, 1997, Pages 153-163

  Grøndahl Hansen, Jan ^a,c   Hilsenbeck, Susan G ^b   Christensen, Ib Jarle ^a   Clark, Gary M ^b   Osborne, C Kent ^b   Brünner, Nils ^a  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Breast cancer; PAI 1; Prognosis; uPA

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CYTOSOL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CYTOSOL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030935698     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005744914124     Document Type: Article

References (42)

1. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN: Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68: 1-19, 1990
2. Axelrod JH, Reich R, Miskin R: Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. Mol Cell Biol 9: 2133-2141, 1989
3. Behrendt N, Rønne E, Ploug M, Petri T. Løber D, Nielsen LS, Schleuning WD, Blasi F, Appella E, Danø K: The human receptor for urokinase plasminogen activator. J Biol Chem 265: 6453-6460, 1990
4. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, Smith HS: Immunohistochcmical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60: 597-603, 1995
5. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866, 1994
6. Cajot JF, Bamat J, Bergonzelli GE, Kruithof EKO, Medcalf RL, Testuz J, Sordat B: Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA 87: 6939-6943, 1990
7. Clark GM, Dressler LG, Owen MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Mcd 320: 627-633, 1989
8. Cox DR: Regression models and life tables (with discussion). J R Statist Soc 187: 187-200, 1972
9. Cubellis MV, Nolli ML, Cassani G, Blasi F: Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 261: 15819-15822, 1986
10. Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079-1085, 1990
11. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985
12. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 62: 531-533, 1988
13. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829, 1990
14. Ellis V, Behrendt N, Danø K: Plasminogen activation by receptor-bound urokinase. J Biol Chem 266: 12752-12758, 1991
15. Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD: The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111: 783-792, 1990
16. Foekens JA, Schmitt M, Van Putten WLJ, Peters HA, Bontenbal M, Jänicke F, Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992
17. Foekens JA, Schmitt M, Van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658, 1994
18. Grøndahl-Hansen J, Christensen U, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993
19. Grøndahl-Hansen J, Peters HA, Van Putten LJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Brünner N, Foekens JA: Prognostic significance of the receptor tor urokinase plasminogen activator in breast eancer. Clin Cancer Res 1: 1079-1087, 1995
20. Hollas W, Blasi F, Boyd D: Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 51: 3690-3695, 1991
21. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H: Both the cytosols and detergent extracts of breast caneer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Caneer Res 54: 2527-2530, 1994
22. Jänicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostasis 17: 303-312, 1991
23. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78, 1990
24. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T: Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52: 3610-3614, 1992
25. Lowry OH, Roseborough NH, Farr AL, Randall RJ: Protein measurment with the folin phenol reagent. J Biol Chem 193: 265-275, 1951
26. Mackinnon WB, Hancock R, Dyne M, Russell P, Mountford CE: Evaluation of an in vitro invasion assay for use on solid tissue samples and cultured cells. Invasion Metastasis 12: 241-252, 1992
27. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 47: 487-498, 1986
28. Nielsen BS, Sehested M, Timshel S, Pyke C. Danø K: Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74: 168-177, 1996
29. Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Danø K: Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 21: 6410-6415, 1982
30. Nykjær A, Petersen CM, Møller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thøgersen HC, Munch M, Andreasen PA: Purified alpha 2-macroglobulin receptor/LDL receptor-related protein bind urokinase plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 267: 14543-14546, 1992
31. Olson D, Pöllänen J, Høyer-Hansen G, Rønne E, Sakaguchi K, Wun TC, Appella E, Danø K, Blasi F: Internalization of the urokinase plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267: 9129-9133, 1992
32. Ossowski L: In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 107: 2437-2445, 1988
33. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-619, 1983
34. Ossowski L, Russo-Payne H, Wilson EL: Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res 51: 274-281, 1991
35. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, Danø K, Grøndahl-Hansen J: Prognostic impact of urokinase. urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675, 1994
36. Pedersen H, Grøndahl-Hansen J, Francis D, Østerlind K, Hansen HH, Danø K, Brünner N: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-123, 1994
37. Peteren LC, Lund LR, Nielsen LS, Danø K, Skriver L: One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 263: 11189-11195, 1988
38. Pyke C, Græm N, Ralfkiær E, Rønne E, Høyer-Hansen G. Brünner N, Danø K: Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911-1915, 1993
39. Quax PHA, Pedersen N, Masucci MT, Weening-Verhoeff EJD, Danø K, Verheijen JH, Blasi F: Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regulation 2: 793-803, 1991
40. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467-474, 1990
41. Rosenquist C, Thorpe SM, Danø K, Grondahl-Hansen J: Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat 28: 223-229, 1993
42. Skriver L, Nielsen LS, Stephens R, Danø K: Plasminogen activator released as in active proenzyme from murine cells transformed by sarcoma virus. Eur J Biochem 124: 409-414, 1982